Care Modules
RENAL
DIABETES
CARDIAC
BEHAVIORAL
RESPIRATORY
Renal Disease
Chronic kidney disease and end-stage
$32 billion ANNUAL ECONOMIC BURDEN
The American Society of Nephrology (ASN) states that the annual economic burden of ESRD is $32 billion
Affects 37 million adults
About 37 million U.S. adults are estimated to have CKD, and most are undiagnosed – IQVIA
40% suffer without diagnosis
40% of people with severely reduced kidney function are not aware of having CKD – IQVIA
According to the CDC, 9 out of 10 adults with CKD do not know they have CKD.
USC Center for Health Policy and Economics states, “patients with ESKD have average monthly spending 33× higher than patients without.
Early Disease burden
Overall health care costs ranged from $26,889 (A1) to $42,139 (A3), and from $28,627 (G2) to $42,902 (G5) per patient per year, demonstrating a considerable early disease burden which continued to increase with declining kidney function. KIREREPORTS Kidney International Reports - February 3, 2023
HIGH PPPY COSTS with commercial payers
The PPPY costs of later stage CKD were particularly notable for patients with concomitant heart failure ($50,191) and those covered by commercial payers ($55,735). KIREREPORTS Kidney International Reports - February 3, 2023
33x higher monthly spending
USC Center for Health Policy and Economics states, “Patients with ESKD have average monthly spending 33× higher than patients without."
"We're looking forward to advancing our AI initiatives to provide a higher level of precision and improve our customers' insights into their own data"
Halt Progression, Reduce Costs.
DeLorean AI's state-of-the-art, pre-trained Renal AI solution identifies individual patients with undiagnosed renal conditions and precisely predicts which patients are on the verge of progressing to CKD and End-State Renal Disease. Physicians supported with Renal AI can precisely identify and effectively intervene with patients in order to halt disease progression and drastically lower overall patient care costs.
Halt progression to CKD and End-State
Identify patients with undiagnosed renal conditions
Lower patient care costs
Enhance nurse and technician performance
Improve patient quality of life
Diabetes
Undiagnosed diabetes, pre-diabetes, diabetes, and type 2 diabetes
38.4 million people have diabetes
38.4 million people have diabetes (11.6% of the US population) – CDC
increasing medical costs
The direct medical costs attributed to diabetes increased by 7% between 2017 and 2022
Nearly $413 Billion in Costs Annually
Annual Costs of Diabetes is currently $412.9 Billion including $306.6 billion in direct medical costs and $106.3 billion in indirect costs - American Diabetes Association November 1, 2023
Millions are undiagnosed
8.7 million adults aged 18 years or older who met laboratory criteria for diabetes were not aware of or did not report having diabetes (undiagnosed diabetes). This number represents 3.4% of all US adults and 22.8% of all US adults with diabetes. - CDC
2.6x Medical expenditures with diabetes
On average, people with diagnosed diabetes have medical expenditures 2.6 time higher than would be expected without diabetes – ADA
INSULIN SPENDING HAS TRIPLED
Spending on insulin tripled in the past 10 years- increasing from $8 billion in 2012 to $22.3 billion in 2022. - ADA
POPULATION GROWING EXPONENTIALLY
By 2060, the diabetes population in the U.S. is expected to double to over 60 million patients, with up to 40% also suffering from CKD, many of whom will remain undiagnosed. IQVIA
Prevention through early prediction
You can prevent or delay prediabetes from turning into type 2 diabetes with simple, proven lifestyle changes. – CDC
Lifestyle changes make a difference
Successful lifestyle changes reduce medication needs for high blood pressure and high cholesterol, and avoid the psychosocial stress associated with developing type 2 diabetes. - NIH
The benefits of screening
The USPSTF concludes that screening for prediabetes and type 2 diabetes and offering or referring patients with prediabetes to effective preventive interventions has a moderate net benefit.
INCREASED TREATMENT COSTS
For patients under the age of 65 with both CKD and T2D, the cost of treatment can be as much as 60% higher than treating T2D alone.
Prevention is possible
Our advanced, pre-trained Diabetes AI platform pinpoints members who have yet to be diagnosed with diabetic ailments, while also accurately forecasting those at imminent risk of advancing from Prediabetes to Type 2. Physicians equipped with our Diabetes AI are empowered to detect at-risk patients with greater precision and intervene effectively, thereby arresting the progression of the disease and significantly reducing the cost of patient care.
Prevent transition to type 2
Identify and treat patients with undiagnosed diabetic conditions
Lower patient care costs
Provide hyper-personalized care
Improve patient quality of life
Enhance nurse and technician performance
Risk CLASSIFICATION OF DISEASE ONSET & PROGRESSION
Diabetes AI makes use of the entire patient population, instead of samples, to ensure sub-populations are captured and comprehensive risk classifications can be assigned to adeptly identify those who are at-risk
HYPER-PERSONALIZED PATIENT VIEW
With the entire population modeled, Diabetes AI can monitor each patient on an individual level and create specific, tailored recommendations for treatment protocols and appropriately provide interventive measures when needed
PREDICT CHANGES IN HEALTH AND TREATMENT
Diabetes AI generates predictions in real-time, as new data enters the environment, monitoring those who are at-risk for developing diseases, transitioning to a worse disease state, or evaluating treatment for patients based on the stage / severity of the disease
NEXT-BEST-ACTION RECOMMENDATIONS TO OPTIMIZE CARE
When differences are detected between predictions and actions, Diabetes AI will make a next-best- action recommendation for the healthcare professional to review and act upon
CARDIAC Disease
Hypertension, ischemic artery disease and heart failure
AFFECTS 119.9 million AMERICANS
Nearly half of adults have hypertension (119.9 million) – MillionHearts
$2000 higher annual spending
Individuals with hypertension are estimated to face nearly $2000 higher annual healthcare expenditure compared with their nonhypertensive peers. - AHA
$131 Billion in Healthcare Costs
Healthcare costs associated with hypertension account for about $131 billion. – AHA
Costs the United States $239.9 Billion a year
Heart disease cost the United States about $239.9 billion each year from 2018 to 2019. This includes the cost of health care services, medicines, and lost productivity due to death. – CDC
a compounding issue
By 2035, nearly half of the U.S. population will have some form of cardiovascular disease. – AHA
$1.1 Trillion projected costs by 2035
The projected costs by 2035 of CVD are $1.1 trillion. – AHA
Identify and Intervene
Leveraging our pre-trained Cardiac AI, we are able to uncover individual cases of undiagnosed heart conditions and accurately determine who is at risk of progressing to more severe stages. This provides clinical teams with the critical ability to identify and proactively address the needs of these patients, preventing disease progression and significantly decreasing the associated healthcare expenses.
Identify patients with undiagnosed hypertension and Ischemic Artery Disease
Predict episodic cardiac events
Lower patient care costs
Provide hyper-personalized care
Improve patient quality of life
Enhance nurse and technician performance
Behavior Health
Major depressive disorders including Mild, Moderate, severe and Psychotic
AFFECTS 45.3 million AMERICANS
Mental illness affects 23% (45.3 million) of non-elderly adults, with 11% having mild conditions, 6% moderate, and 6% severe conditions. - KFF
associated with higher spending
Having a mental health disorder was associated with substantially higher spending on for other medical conditions, which increased total spending associated with mental health disorders 3-fold. JAMA
HYPER-PERSONALIZED PATIENT VIEW
With the entire population modeled, Behavioral Health AI can monitor each patient on an individual level and create specific, tailored recommendations for treatment protocols and appropriately provide interventive measures when needed
Identify Undiagnosed Patients
DeLorean AI's state-of-the-art, pre-trained Behavioral Health AI identifies individual patients with undiagnosed behavioral health issues. Clinical teams supported with Behavioral AI can precisely identify and effectively intervene with patients in order to halt disease progression and drastically lower overall patient care costs.
Halt progression to advanced disease stages
Lower patient care costs
Improve patient quality of life
Enhance nurse and technician performance
Renal Disease
Chronic kidney disease and end-stage
$32 billion ANNUAL ECONOMIC BURDEN
The American Society of Nephrology (ASN) states that the annual economic burden of ESRD is $32 billion
Affects 37 million adults
About 37 million U.S. adults are estimated to have CKD, and most are undiagnosed – IQVIA
40% suffer without diagnosis
40% of people with severely reduced kidney function are not aware of having CKD – IQVIA
According to the CDC, 9 out of 10 adults with CKD do not know they have CKD.
USC Center for Health Policy and Economics states, “patients with ESKD have average monthly spending 33× higher than patients without.
Early Disease burden
Overall health care costs ranged from $26,889 (A1) to $42,139 (A3), and from $28,627 (G2) to $42,902 (G5) per patient per year, demonstrating a considerable early disease burden which continued to increase with declining kidney function. KIREREPORTS Kidney International Reports - February 3, 2023
HIGH PPPY COSTS with commercial payers
The PPPY costs of later stage CKD were particularly notable for patients with concomitant heart failure ($50,191) and those covered by commercial payers ($55,735). KIREREPORTS Kidney International Reports - February 3, 2023
33x higher monthly spending
USC Center for Health Policy and Economics states, “Patients with ESKD have average monthly spending 33× higher than patients without."
"We're looking forward to advancing our AI initiatives to provide a higher level of precision and improve our customers' insights into their own data"
Halt Progression, Reduce Costs.
DeLorean AI's state-of-the-art, pre-trained Renal AI solution identifies individual patients with undiagnosed renal conditions and precisely predicts which patients are on the verge of progressing to CKD and End-State Renal Disease. Physicians supported with Renal AI can precisely identify and effectively intervene with patients in order to halt disease progression and drastically lower overall patient care costs.